Jev, it kind of puts things into perspective a bit, in regards to POH's enthusiasm about the recent oxymorphone results, which in mine and others opinion showed we have fully functioning one of kind patch that just needs to cross some low lying hurdles to reach the projected targets. And before anyone questions why they are low lying hurdles, including the FDA, and phase II/III's, just have to re-read many posts outlining why, however in summary it is an existing tested drug, that has been shown via the patch to provide stable therapeutic doses for drugs that in their current oral forms have myriads of serious problems.
POH Price at posting:
12.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)